



SAPIENZA
UNIVERSITÀ DI ROMA

TODO Titolo

Faculty of Information Engineering, Computer Science and Statistics
Bachelor's Degree in Computer Science

Alessio Bandiera
ID number 1985878

Advisor
Prof. Ivano Salvo

Academic Year 2023/2024

TODO Titolo

Bachelor's Thesis. Sapienza University of Rome

© 2024 Alessio Bandiera. All rights reserved

This thesis has been typeset by L^AT_EX and the Sapthesis class.

Author's email: alessio.bandiera02@gmail.com

TODO. test

Contents

1	Introduction	1
1.1	Cancer therapy	1
1.1.1	Current treatment	1
1.1.2	Target therapy	2
2	Driver mutations	3
2.1	Mutations	3
2.1.1	Passenger and driver mutations	3
2.2	Classifying mutations	4
2.2.1	Frequency	4
2.2.2	Mutual exclusivity and coverage	4
2.3	Mutual exclusivity formalization	5
2.3.1	Hard and soft mutual exclusivity	5
2.3.2	Mutual exclusivity of a group	5
2.3.3	Dendrix	6
2.3.4	Multi-Dendrix	7
2.3.5	Mutex	8
2.3.6	C3	8
3	Finding driver mutations	11
3.1	Approaches	11
3.1.1	Dendrix	11
3.1.2	Multi-Dendrix	11
3.1.3	MDPFinder	11
3.1.4	Mutex	11
3.1.5	C3	11

Acknowledgements	12
------------------	----

Chapter 1

Introduction

Cancer is a medical condition characterized by uncontrolled cell proliferation, which allows cells to infiltrate into organs and tissues, thereby altering their functions and structure. This exponential growth is driven by mutations in cellular DNA, which encodes the instructions for cell development and multiplication, therefore errors in these instructions can lead to cancerous transformation. In most types of cancer, a single aberration is insufficient for cancer development; instead, multiple mutations are required. Some of these mutations are present since birth, while others occur throughout life due to chance or lifestyle choices. Additionally, for tumor proliferation to occur, mutations in genes that regulate cell growth are necessary [14]. Specifically, proto-oncogenes, which promote mitosis, and tumor suppressor genes, which inhibit cell growth, are involved in this process, known as *oncoevolution* [4].

expand this introduction

1.1 Cancer therapy

1.1.1 Current treatment

Research aimed at finding a cure for cancer is continuously evolving due to the tumor's lethality and complexity. Currently, the primary techniques used to remove, control, manage, and delay the effects of cancer include [2]:

- **surgery**, which involves the removal of the cancerous region and is generally reserved for solid tumors;
- **radiotherapy**, which uses x-rays to destroy tumor cells, aiming to target the cancerous region as precisely as possible to preserve healthy tissue; however, radiotherapy can increase the risk of developing secondary tumors, such as leukemia or sarcomas, and may lead to delayed effects like dementia, amnesia, or progressive cognitive difficulties;
- **chemotherapy**, which employs cytotoxic drugs to block cellular division in both cancerous and healthy cells, but they can also induce side effects in rapidly renewing tissues.

- **hormone therapy**, which alters the balance of specific hormones, potentially leading to side effects such as joint pain or osteoporosis;
- **targeted therapy**, which involves drugs containing antibodies or inhibitory substances that specifically target cancer cells, promoting their destruction by the immune system; however, developing effective targeted therapies can be challenging due to the complexity of the target's structure or function; in addition, this approach may also induce unwanted side effects in various organs, and cancer cells may develop resistance if they find alternative ways to develop that do not rely on the therapy's target [\[13\]](#).

check this out

1.1.2 Target therapy

In particular, in recent years targeted therapy has been the focus of extensive research due to its potential to precisely affect only the desired target, thereby reducing the side effects that currently characterize most cancer treatments and potentially limiting damage to healthy cells [\[12\]](#).

expand target therapy on how it works; check README for link

Chapter 2

Driver mutations

Cell signaling is the process by which cells interact with each other, themselves, or their environment. It concerns the transduction of signals, which can be chemical, or can involve various types such as pressure, temperature, or light signals [5]. **Pathways** are sequences of molecular interactions within a cell that lead to a change in the cell or the production of a specific product [11]. These pathways have a direction in which the actions occur, with the terms *upstream* and *downstream* indicating the initial and final stages of these processes, respectively.

In cancer research, **signaling pathways** are of particular interest because they mediate the transduction of cell signals. Identifying and targeting the signaling pathways responsible for cancer growth could potentially halt the development of the disease.

check this out, also check if what i wrote is actually true, i think i read it somewhere but can't find the source right now; expand on cell signaling? expand of pathways? if yes, make subsections

2.1 Mutations

2.1.1 Passenger and driver mutations

There are two types of mutations in cancer: **passenger mutations** and **driver mutations**. Passenger mutations do not confer direct benefits to tumor growth or development, whereas driver mutations actively contribute to cancer progression by providing an evolutionary advantage and promoting the proliferation of tumor cells. A **driver gene** is a gene that harbors at least one driver mutation, though it may also contain passenger mutations . A driver pathway consists of at least one driver gene. Driver mutations, genes, and pathways are of significant scientific interest due to their crucial role in cancer proliferation.

DO I ADD THIS AS A CITATION???

Driver genes can be classified into 12 signaling pathways, which regulate cellular functions related to survival, fate, and genomic maintenance.

use (and expand) this? same source as prev

2.2 Classifying mutations

2.2.1 Frequency

To classify mutations into the two categories described, assessing their biological function is essential, though this remains a challenging task. Numerous methods exist to predict the functional impact of mutations based on *a priori* knowledge. However, these approaches often fail to integrate information effectively across various mutation types and are limited by their reliance on known proteins, rendering them less effective for less-studied ones [10].

With the decreasing cost of DNA sequencing, it is now possible to categorize mutations by examining their frequency, as driver mutations are typically the most recurrent in patients' genomes [10]. Indeed, key driver events, such as TP53 loss-of-function mutations, can be identified by their significantly high frequency of occurrence across a set of tumors [1]. However, in many cases, since driver mutations are predominantly located in genes that are part of cell signaling pathways, different patients may harbor mutations in different pathway loci. Indeed, driver mutations can vary extensively between patient samples, even within the same cancer type [10]; additionally, there is minimal overlap of mutated genes across sample pairs, even from the same patient [15], reducing the statistical power of frequency analyses.

Moreover, multiple alternative driver alterations in different genes may lead to similar downstream effects. In such instances, the selective advantage is distributed among the alterations frequencies of these genes. In current cancer genomics studies, where the number of samples is significantly smaller than the number of genes profiled per sample, frequency-based methods lack the statistical efficacy to distinguish passenger and driver mutations [1].

Therefore, studies should be conducted at the pathway level, as it is well established that different mutations can affect the same pathway across multiple samples [10]. However, since each pathway involves multiple genes, numerous possible combinations of driver mutations could impact a crucial cancer pathway, making it computationally unfeasible to test every possible gene permutation [6] — estimates suggest that the human genome contains more than 50,000 genes [8]. Hence, it is necessary to identify a property to leverage to conduct the research efficiently.

2.2.2 Mutual exclusivity and coverage

Most techniques developed in recent years for recognizing driver mutations leverage a statistical property observed in cancer patient data: each patient typically has a relatively small number of mutations that affect multiple pathways, thus each pathway will contain *1 driver mutation on average* per sample. This concept of mutual exclusivity among driver mutations within the same pathway, as statistically observed in patient samples, is then axiomatized and employed by research algorithms designed to identify driver mutations [10]. Additionally, mutual exclusivity *does not affect different pathways*; it is a phenomenon that occurs exclusively within a single pathway. While the precise explanation for this occurrence is not yet fully

understood, several hypotheses appear promising [7, 3, 6]:

- one hypothesis is that mutually exclusive genes are functionally connected within a common pathway, acting on the same downstream effectors and creating functional redundancy; consequently, they would share the same selective advantage, meaning that the alteration of one mutually exclusive gene would be sufficient to disrupt their shared pathway, thereby removing the selective pressure to alter the others; this explanation, however, does not fully account for the phenomenon because the co-alteration of mutually exclusive genes should not result in negative effects on the cell.
- an alternative explanation is that the co-occurrence of mutually exclusive alterations is detrimental to cancer survival, leading to the elimination of cells that harbor such co-occurrences; moreover, some pairs of mutually exclusive genes could be *synthetic lethal*, meaning that while the alteration of one gene may be compatible with cell survival, the simultaneous aberration of both genes would be lethal to the cell .

In addition, another key property of driver pathways is **coverage**, i.e. driver genes constituting a driver pathway are frequently mutated across many samples.

Thus, *a driver pathway consists of genes that are mutated in numerous patients, with mutations being approximately mutually exclusive*. It is also observed that pathways exhibiting these characteristics are generally shorter and comprised of fewer genes on average [10].

add example from survey paper?; also, use example? (mail "Risposte (parziali) alle questioni, ERG e SPOP")

2.3 Mutual exclusivity formalization

2.3.1 Hard and soft mutual exclusivity

In the statistical literature, two types of mutual exclusivity are defined: **hard** and **soft**. Hard mutual exclusivity describes events that are presumed to be strictly mutually exclusive, with the null hypothesis being that any observed overlap is due to random errors. However, in this context, it is not feasible to test for hard mutual exclusivity, as this is a property observed statistically from patient data. Therefore, it is necessary to relax the constraint to soft mutual exclusivity, where two otherwise independent events overlap less than expected by chance due to some statistical interaction [1].

2.3.2 Mutual exclusivity of a group

Searching for the most mutually exclusive gene group is equivalent to identifying a single driver pathway, for the aforementioned reasons. For a pair of genes, soft mutual exclusivity can be assessed using the Fisher's exact test. However, there is no agreed-upon method for analytically testing mutual exclusivity among more than two genes. One approach could involve checking whether each pair of genes within

the group exhibits mutual exclusivity; this method, however, may be overly strict, as a gene set can exhibit a strong mutual exclusivity pattern as a whole even if no individual pairs show any [1].

2.3.3 Dendrix

The author's of a very well-known paper, which developed two algorithms called "Dendrix" [6], gave the following mathematical formalization to the properties of mutual exclusivity and coverage for a set of genes. Consider a so-called "mutation matrix" A , with m rows and n columns, where each row represents a patient and each column represents a gene; the entry $a_{i,j}$ is equal to 1 if and only if gene j is mutated in patient i .

	g_1	g_2	g_3
p_1	0	1	0
p_2	1	1	0
p_3	0	0	1

Table 2.1. A mutation matrix.

Given a gene g , let

$$\Gamma(g) := \{i \mid a_{i,g} = 1\} \quad (2.1)$$

denote the set of patients which have g mutated; furthermore, given a set of M genes, let the **coverage** be

$$\Gamma(M) := \bigcup_{g \in M} \Gamma(g) \quad (2.2)$$

which denotes *the set of patients in which at least one of the genes in M is mutated*. Under the previous definitions of mutual exclusivity, we say that a set M of genes is **mutually exclusive** if *no patient has more than one mutated gene*, formally

$$\forall g, g' \in M \quad \Gamma(g) \cap \Gamma(g') = \emptyset \quad (2.3)$$

Any gene set can be thought of as a $m \times k$ submatrix of a mutation matrix A , up to rearranging A 's columns — their order does not matter since they represent genes. Accordingly, such a submatrix is said to be **mutually exclusive** if *each row contains at most one 1*.

Furhermore, given a gene set M , the following properties are formalized:

- i) coverage:* most patients have at least one mutation in M ;
- ii) approximate exclusivity:* most patients have exactly one mutation in M .

To evaluate these two attributes, a measure that quantifies the trade-off between coverage and mutual exclusivity is introduced. Given a set M of genes, the **coverage overlap** is defined as follows:

$$\omega(M) := \sum_{g \in M} |\Gamma(g)| - |\Gamma(M)| \quad (2.4)$$

Note that the sum in Equation 2.4 is the number of 1s in M 's corresponding submatrix; e.g. considering Table 2.1, if $M = \{g_1, g_2\}$ then

$$\omega(M) = |\Gamma(g_1)| + |\Gamma(g_2)| - |\Gamma(\{g_1, g_2\})| = |\{p_2\}| + |\{p_1, p_2\}| - |\{p_1, p_2\}| = 1 + 2 - 2 = 1$$

which shows that $\omega(M)$ is the *number of patients that are counted more than once in the sum*. Indeed, $\omega(M) = 0$ only if the sum equals the coverage of M , and this can only happen if no patient has more than one mutated gene of M ; in fact, when $\omega(M) \geq 0$, M is said to be **mutually exclusive**.

come fa ad essere negativo?

Given a set of genes M , to take into account both coverage and coverage overlap, the following measure is introduced:

$$W(M) := |\Gamma(M)| - \omega(M) = 2 |\Gamma(M)| - \sum_{g \in M} |\Gamma(g)| \quad (2.5)$$

Note that $W(M) = |\Gamma(M)|$ when M is mutually exclusive. In order to find an optimal gene set, the following problem has to be solved:

Maximum Weight Submatrix Problem: Given an $m \times n$ mutation matrix A , and an integer $k > 0$, find the $m \times k$ submatrix of A that maximizes $W(M)$.

Finding the solution to this problem is computationally difficult even for small values of k (e.g there are $\approx 10^{23}$ subsets of size $k = 6$ of 20,000 genes), and it can be proven that it is NP-Hard.

nei materiali supplementari mettono la dimostrazione che questo problema è NP-Hard, lo devo fare?

2.3.4 Multi-Dendrix

Multi-Dendrix aims to refine Dendrix's weight function to extend the metric to assess mutual exclusivity across multiple driver pathways. In particular, while identifying individual driver pathways is crucial, most cancer patients are likely to have driver mutations across multiple pathways.

To effectively identify multiple driver pathways, it is necessary to establish criteria for evaluating potential *collections of gene sets*. Based on the same biological reasoning mentioned earlier, it is expected that each pathway will contain approximately one driver mutation. Furthermore, since each driver pathway is crucial for cancer development, it is expected that most patients will harbor a driver mutation in most driver pathways. Consequently, high exclusivity is predicted within the genes of each pathway, along with high coverage of each pathway individually. One metric that meets these criteria is to find a collection $M = \{M_1, \dots, M_t\}$ of gene sets which maximizes the sum of individual weights, i.e. $\sum_{i=1}^t W(M_i)$ [10].

2.3.5 Mutex

in questo ambito si riferiscono tutti per cognome, esempio Vandin et. al, dovrei farlo anche io o posso limitarmi a scrivere "authors?"

ci sono esempi in file supplementari, li guardo?

QUESTO paper fa vedere in dettaglio come si fa, sono sicuro al 99% che si tratti della stessa cosa, lo inserisco?

specificare quali di preciso? non mi sembra rilevante

Mutex's authors criticize Dendrix's metric because it has a strong bias toward highly mutated genes, and in some instances, the excessive emphasis on coverage leads to both false positives and negatives. . They propose a metric that extends Fisher's exact test — also known as *hypergeometric test* — to quantify the mutual exclusivity between multiple measurements [1].

Specifically, the alteration of a pair of genes is defined to be **mutually exclusive** if *their overlap in samples is significantly less than expected by chance*, and this can be assessed through a hypergeometric test. It is important to note that a uniform alteration frequency across may not always hold, particularly for hyper-mutated samples often resulting from prior mutations in DNA repair mechanisms. Addressing this heterogeneity is challenging, as each overlap in the null model has a different probability. This remains an open problem, and to partially mitigate it, albeit at the cost of statistical power, hyper-altered samples are excluded from the analysis.

Mutex's authors also developed a metric to assess the mutual exclusivity of a group of genes. Consider the following null hypothesis:

H_0 : The specific member gene in the group is altered independently from the union of other alterations in the group.

Using Dendrix's notation, H_0 states that for a given gene set M , for every gene $i \in M$, mutations in $\Gamma(i)$ are independent of alterations in $\Gamma(M - \{i\})$. H_0 is then tested for each $i \in M$ by evaluating the co-distribution of i with the union of the others through Fisher's exact test, generating $|M|$ p -values. These p -values represent the probabilities for the independent distribution of each member gene. To ensure that every member of the group contributes to the pattern, the least significant — i.e. the largest — p -value of the group is used as the initial score of the group. Using Dendrix's notation

non so come funziona di preciso il test di Fisher, dovrei vederlo?

i'm not sure i know what this means

$$s_0 := \max_{i \in M} H(\Gamma(i), \Gamma(M - \{i\})) \quad (2.6)$$

where s_0 is the initial score, and H is the hypergeometric test. Since multiple groups are being tested, s_0 is affected by multiple hypothesis testing. To account for it, first the null distribution of the initial p -values must be estimated for each gene, then it must be calculated the significance of the observed initial p -values for each member

add link?

From this second set of p -values, the least significant one is selected as the multiple hypothesis testing corrected final score.

2.3.6 C3

Another notable approach utilized in several papers involves constructing gene graphs and identifying clusters based on specific criteria. An example of this method is demonstrated by the authors of C3 [9].

non ho la minima idea di cosa voglia dire tutta questa frase; successivamente, qui viene spiegato in che modo stimano la "null distribution of the initial p-value", ma oltre che non riesco a capire che cosa facciano di preciso, per farlo riciclano l'algoritmo con il quale poi andranno a risolvere il problema generale, ma io non l'ho menzionato perché intendevo parlare di come questi paper risolvono indipendentemente il problema in un capitolo successivo, cosa dovrei fare? saltare? non sono neanche in grado di stabilire quanto sia rilevante

talk about the last paragraph, which is even less comprehen-

Let $G = (V, E)$ be a *complete graph* of genes, thus an edge exists between any pair of vertices. Each edge $(u, v) \in E(G)$ is assigned two weights:

- a **positive weight** w_{uv}^+ , which represents *the cost of placing u and v in different clusters*;
- a **negative weight** w_{uv}^- , which represents *the cost of placing u and v in the same cluster*;

i.e. by making w_{uv}^+ large, placing u and v in different clusters is discouraged, and viceversa; the same concept applies for w_{uv}^- . Indeed, as weights representations suggest, *genes in the same cluster are likely to be mutually exclusive*.

Weights are calculated using four types of datasets: gene mutation data, copy number variation (CNV), network information, and gene expression data. To appropriately combine the sources from which the information was obtained, linear combinations were utilized to account for the reliability of the sources from which the data was drawn.

Additionally, as each type of data contributes differently to the driver discovery process, linear combinations are used, based on the importance or accuracy of each, specifically:

- the (e) label refers to *exclusivity*;
- the (c) label refers to *coverage*;
- the (n) label refers to *network information*;
- the (x) label refers to *expression data*.

Let A be a $m \times n$ mutation matrix, as described in Table 2.1. In addition, let C be a $m \times n$ matrix representing the CNV data, where $c_{i,j} = 0$ means that there is no change in the copy number of gene j in sample i , otherwise, the corresponding number reflects the deviation of the CNV number from its baseline — hence, C contains both positive and negative values. Following this, a binary matrix M is constructed combining A and C as follows:

$$m_{i,j} = 0 \iff \begin{cases} a_{i,j} = 0 \\ l_{\text{cnv}} < c_{i,j} < h_{\text{cnv}} \end{cases} \quad (2.7)$$

where l_{cnv} and h_{cnv} are lower and upper bounds on copy numbers that determine the significance level. Therefore, if $m_{i,j} = 0$, no mutation of gene j is recorded in sample i , otherwise gene j is deemed mutated.

Given a gene u , i.e. a vertex of G , C3's authors use $\mathcal{S}(u)$ to denote the *set of patients in which u is altered*, namely

$$\mathcal{S}(u) := \{i \mid m_{i,u} = 1\} \quad (2.8)$$

menziono i valori che hanno usato loro? menziono le conseguenze che valori alti/bassi di queste soglie hanno, secondo loro?

which corresponds to $\Gamma(u)$ under Dendrix's notation, defined through the M matrix respectively.

Negative weights only depend on the **mutual exclusivity** component, which is defined as follows:

$$w_{uv}^- := w_{uv}^-(e) = a \cdot \frac{|\mathcal{S}(u) \cap \mathcal{S}(v)|}{\min(|\mathcal{S}(u)|, |\mathcal{S}(v)|)} \quad (2.9)$$

where a is a user-defined scaling parameter. This ratio is often referred to as **IoM** (*Intersection over Minimum*), and suits the criteria of mutual exclusivity because the fewer patients who have both u and v mutated, the smaller the weight, making it more plausible that u and v are mutually exclusive, therefore the cost of placing them in the same cluster should be low. Note that

$$\forall u, v \in V(G) \quad a = 1 \implies 0 \leq w_{uv}^- \leq 1 \quad (2.10)$$

By contrast, positive weights can depend on multiple factors which will be presented in the following sections. Focusing on **coverage**, if two genes u and v increase the coverage of the set significantly, $w_{uv}^+(c)$ should be large such that they are encouraged to be placed in the same cluster. Let

$$D(u, v) := |\mathcal{S}(u) \Delta \mathcal{S}(v)| \quad (2.11)$$

where Δ denotes the symmetric difference of two sets; a large value of $D(u, v)$ suggests that u and v should be placed in the same cluster. Also, let

$$\mathcal{D} := \{D(u, v) \mid u, v \in V(G)\} \quad (2.12)$$

and let $T(J)$ be the J -th percentile of the values in \mathcal{D} . The coverage component of positive weights is defined as follows:

$$w_{uv}^+(c) := \begin{cases} 1 & D(u, v) > T(J) \\ \frac{D(u, v)}{T(J)} & D(u, v) \leq T(J) \end{cases} \quad (2.13)$$

Note that, similar to [Equation 2.10](#)

$$\forall u, v \in V(G) \quad 0 \leq w_{uv}^+(c) \leq 1 \quad (2.14)$$

The linear combinations that define w_{uv}^+ will be discussed afterward.

va bene se la metto
su questo piano?

Chapter 3

Finding driver mutations

Although the true explanation for mutual exclusivity remains unknown, and its therapeutic potential is still uncertain, this phenomenon is frequently observed in data and is thought to potentially lead to discoveries in cancer treatment. Existing approaches can be categorized into two types: *de novo* approaches, which identify mutually exclusive patterns using only genomic data from patients, and *knowledge-based* methods, which integrate the analysis with external *a priori* information [7]. *De novo* approaches might lack sufficient information as they do not utilize existing databases. Conversely, given that our understanding of gene and protein interactions in humans is still incomplete and many pathway databases fail to accurately represent the specific pathways and interactions present in cancer cells, *knowledge-based* approaches may be limited by their dependence on existing data sources. Consequently, *de novo* methods might yield new but potentially less accurate results, while *knowledge-based* approaches may limit the discovery of novel biological insights [10].

3.1 Approaches

3.1.1 Dendrix

3.1.2 Multi-Dendrix

3.1.3 MDPFinder

3.1.4 Mutex

3.1.5 C3

nel capitolo precedente l'ho menzionato, cosa dovrei fare? parlarne? io non l'ho analizzato perché parla di Catene di Markov e Monte Carlo (MCMC), lascio perdere e non faccio una sezione per lui?

Acknowledgements

TODO

Bibliography

- [1] Özgün Babur, Mithat Gönen, Bülent Arman Aksoy, et al. “Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations”. In: *Genome Biology* 16.1 (Feb. 2015). ISSN: 1474-760X. DOI: 10.1186/s13059-015-0612-6. URL: <http://dx.doi.org/10.1186/s13059-015-0612-6>.
- [2] *Cancro: la cura*. URL: <https://www.airc.it/cancro/affronta-la-malattia/guida-alle-terapie/cancro-la-cura>.
- [3] Jaroslaw Cisowski and Martin O. Bergo. “What makes oncogenes mutually exclusive?” In: *Small GTPases* 8.3 (July 2016), 187–192. ISSN: 2154-1256. DOI: 10.1080/21541248.2016.1212689. URL: <http://dx.doi.org/10.1080/21541248.2016.1212689>.
- [4] Wikipedia contributors. *Carcinogenesis*. July 2024. URL: <https://en.wikipedia.org/wiki/Carcinogenesis>.
- [5] Wikipedia contributors. *Cell signaling*. Aug. 2024. URL: https://en.wikipedia.org/wiki/Cell_signaling.
- [6] Yulan Deng, Shangyi Luo, Chunyu Deng, et al. “Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability”. In: *Briefings in Bioinformatics* 20.1 (Aug. 2017), 254–266. ISSN: 1477-4054. DOI: 10.1093/bib/bbx109. URL: <http://dx.doi.org/10.1093/bib/bbx109>.
- [7] Yulan Deng, Shangyi Luo, Chunyu Deng, et al. “Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability”. In: *Briefings in Bioinformatics* 20.1 (Aug. 2017), 254–266. ISSN: 1477-4054. DOI: 10.1093/bib/bbx109. URL: <http://dx.doi.org/10.1093/bib/bbx109>.
- [8] Chris Fields, Mark D. Adams, Owen White, et al. “How many genes in the human genome?” In: *Nature Genetics* 7.3 (July 1994), 345–346. ISSN: 1546-1718. DOI: 10.1038/ng0794-345. URL: <http://dx.doi.org/10.1038/ng0794-345>.
- [9] Jack P. Hou, Amin Emad, Gregory J. Puleo, et al. “A new correlation clustering method for cancer mutation analysis”. In: *Bioinformatics* 32.24 (Aug. 2016), 3717–3728. ISSN: 1367-4811. DOI: 10.1093/bioinformatics/btw546. URL: <http://dx.doi.org/10.1093/bioinformatics/btw546>.

- [10] Mark D. M. Leiserson, Dima Blokh, Roded Sharan, et al. “Simultaneous Identification of Multiple Driver Pathways in Cancer”. In: *PLoS Computational Biology* 9.5 (May 2013). Ed. by Niko Beerenwinkel, e1003054. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.1003054. URL: <http://dx.doi.org/10.1371/journal.pcbi.1003054>.
- [11] Nhgri. *Biological Pathways Fact sheet*. Mar. 2019. URL: <https://www.genome.gov/about-genomics/fact-sheets/Biological-Pathways-Fact-Sheet>.
- [12] Cleveland Clinic Medical Professional. *Targeted therapy*. May 2024. URL: <https://my.clevelandclinic.org/health/treatments/22733-targeted-therapy>.
- [13] *Targeted therapy for cancer*. May 2022. URL: <https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies>.
- [14] Bert Vogelstein and Kenneth W Kinzler. “Cancer genes and the pathways they control”. In: *Nature Medicine* 10.8 (July 2004), 789–799. ISSN: 1546-170X. DOI: 10.1038/nm1087. URL: <http://dx.doi.org/10.1038/nm1087>.
- [15] Junfei Zhao, Shihua Zhang, Ling-Yun Wu, et al. “Efficient methods for identifying mutated driver pathways in cancer”. In: *Bioinformatics* 28.22 (Sept. 2012), 2940–2947. ISSN: 1367-4803. DOI: 10.1093/bioinformatics/bts564. URL: <http://dx.doi.org/10.1093/bioinformatics/bts564>.